Palantir Technologies Inc (NYSE:PLTR) shares are trading higher Wednesday. Reports suggest the company is closing in on a contract to overhaul the UK's National Health Service.
What To Know: According to a Bloomberg report, Palantir has emerged as the top pick for a five-year contract with the UK's National Health Service worth up to $579 million.
People familiar with the discussions said the deal is awaiting final approval, but could be announced as soon as this month. It's also possible the deal could be extended for two additional years.
The report indicates that it's considered controversial because several patient advocacy groups have expressed concerns about the data Palantir would have access to. In late August, the agency's chief data officer said software partners would never have access to data for any purpose other than as directed and noted patients would have a say in how their information is used.
Palantir has been working with the UK government since the Covid-19 pandemic, helping oversee the company's vaccine distribution process for a minimal fee, which helped create a positive relationship between the agency and the data firm.
Palantir on Wednesday also announced that it will collaborate with PwC to help clients realize the value of data and AI-enabled operations. PwC will use Palantir's foundry platform to help businesses take actions that create value and transform their work operationally.
Palantir has a Street-high price target of $34 and a Street-low target of $5. The stock is up more than 130% since the start of the year.
See Also: Microsoft's Bing Chat Lets Users Reap Benefits Of OpenAI's DALL-E 3 For Free
PLTR Price Action: Palantir shares were up 4.23% at $15.51 at the time of publication, according to Benzinga Pro.
Photo: Cory Doctorow from Flickr.
$パランティア・テクノロジーズ (PLTR.US)$の株価は水曜日に上昇。
知っておくべきこと:ブルームバーグの報道によると、パランティアは英国国民保健サービスとの5年間の契約(最大5億7900万ドル相当)の最有力候補に浮上したという。
協議に詳しい関係者によると、契約は最終承認待ちだが、早ければ今月中にも発表される可能性があるという。また、契約がさらに2年延長される可能性もある。
同報告書によると、複数の患者擁護団体が、同社がアクセスできるデータについて懸念を表明しているため、物議を醸しているとみられている。8月下旬、同局のチーフ・データ・オフィサーは、ソフトウェア・パートナーは指示された目的以外でデータにアクセスすることはなく、患者は自分の情報がどのように使われるかについて発言権を持つと述べた。
Covid-19パンデミック以来、同社はイギリス政府と協力し、最小限の手数料でワクチン配布プロセスの監督を支援している。
また、パランティアは水曜日、PwCと協業し、データとAIを活用した業務の価値を実現できるよう支援することも発表した。PwCは同社のファウンドリ・プラットフォームを利用し、企業の価値創造をサポートし、オペレーション変革を支援する。